[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:malignant-peritoneal-neoplasm":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":142,"states":143},"Malignant Peritoneal Neoplasm",21,18,[8,16,22,29,35,42,48,54,60,67,73,79,85,92,98,104,110,116,122,129,135],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06930755","Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer",[12],"Phase 1","RECRUITING","2026-08-26T02:18:19.586423Z","2026-07-05T05:32:16.707225Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT04516447","A Study of Azenosertib (ZN-c3) in Patients With Ovarian Cancer",[12],"2026-08-26T02:15:43.339060Z","2026-05-05T02:43:29.538962Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":27,"content_modified":28},"NCT05887609","An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib",[26],"Phase 2","2026-08-26T02:19:16.454910Z","2026-05-05T02:43:29.336719Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":33,"content_modified":34},"NCT06617923","Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer",[26],"2026-08-26T02:17:46.653867Z","2026-05-05T02:43:29.295095Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":40,"content_modified":41},"NCT05080946","Using Aspirin to Improve Immunological Features of Ovarian Tumors",[39],"Early Phase 1","2026-08-26T02:17:18.747857Z","2026-05-05T02:43:29.041300Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT07001592","Intra-tumoral (IT) Injection of vvDD-hIL2-2-RG-1 for Metastatic Gastrointestinal and Peritoneal Tumors",[12],"2026-08-26T02:16:44.178623Z","2026-05-05T02:43:28.887551Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT06305299","Autologous CAR-T Cells Targeting B7H3 in Ovarian Cancer iC9-CAR.B7-H3 T Cells",[12],"2026-08-26T02:16:54.044282Z","2026-05-05T02:43:28.485998Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT05071937","ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer",[26],"2026-08-26T02:15:52.238965Z","2026-05-05T02:43:26.688939Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":65,"content_modified":66},"NCT05377996","A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors",[64],"Phase 1\u002FPhase 2","2026-08-26T02:18:58.141497Z","2026-07-05T05:32:16.802263Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT06276491","Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors",[12],"2026-08-26T02:19:19.162260Z","2026-07-05T05:32:16.747857Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT06796907","A Study of Mocertatug Rezetecan in Combination With Anti-cancer Therapies for Advanced Solid Tumors",[64],"2026-08-26T02:15:21.365312Z","2026-05-29T15:36:40.171786Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":83,"content_modified":84},"NCT04196257","BP1001-A in Patients With Advanced or Recurrent Solid Tumors",[12],"2026-08-26T02:17:33.002248Z","2026-05-05T02:43:28.964891Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":90,"content_modified":91},"NCT05804370","Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)",[89],"Phase 3","2026-08-26T02:15:17.167444Z","2026-05-05T02:43:29.706359Z",{"nct_id":93,"title":94,"phases":95,"status":13,"updated_at":96,"content_modified":97},"NCT04701645","Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer",[12],"2026-08-26T02:18:03.638950Z","2026-05-05T02:43:28.398374Z",{"nct_id":99,"title":100,"phases":101,"status":13,"updated_at":102,"content_modified":103},"NCT07489287","GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer",[12],"2026-08-26T02:16:35.654046Z","2026-06-14T18:39:22.247991Z",{"nct_id":105,"title":106,"phases":107,"status":13,"updated_at":108,"content_modified":109},"NCT00488878","Data Collection for Patients With Low Grade Ovarian or Peritoneal Tumors",[],"2026-08-26T02:18:18.766496Z","2026-05-13T02:55:06.037418Z",{"nct_id":111,"title":112,"phases":113,"status":13,"updated_at":114,"content_modified":115},"NCT01034033","Genetic & Pathological Studies of BRCA1\u002FBRCA2: Associated Tumors & Blood Samples",[],"2026-08-26T02:19:30.857183Z","2026-05-13T02:55:06.066896Z",{"nct_id":117,"title":118,"phases":119,"status":13,"updated_at":120,"content_modified":121},"NCT05547321","Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors.",[12],"2026-08-26T02:15:54.846520Z","2026-05-05T02:43:28.476219Z",{"nct_id":123,"title":124,"phases":125,"status":126,"updated_at":127,"content_modified":128},"NCT07653594","TRANScriptional Pathways Of Surgical Pain Modulated by Music Therapy Exposure (TRANSPOSE)",[],"NOT_YET_RECRUITING","2026-08-26T02:17:53.433613Z","2026-06-17T19:21:16.686578Z",{"nct_id":130,"title":131,"phases":132,"status":126,"updated_at":133,"content_modified":134},"NCT06694142","Feasibility of Addressing Sexual Dysfunction in Women with Breast and Gynecologic Cancers with a Novel Mobile Application",[],"2026-08-26T02:18:33.598205Z","2026-05-05T02:43:29.078926Z",{"nct_id":136,"title":137,"phases":138,"status":139,"updated_at":140,"content_modified":141},"NCT05445778","Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer",[89],"ACTIVE_NOT_RECRUITING","2026-08-03T03:31:16.569358Z","2026-05-05T02:43:29.220044Z",[],[144,148,152,155,159,163,166,169,172,175,178,182,185,188,191,195,198,201],{"state":145,"count":146,"slug":147},"Pennsylvania",8,"pennsylvania",{"state":149,"count":150,"slug":151},"New York",7,"new-york",{"state":153,"count":150,"slug":154},"Texas","texas",{"state":156,"count":157,"slug":158},"California",6,"california",{"state":160,"count":161,"slug":162},"Florida",5,"florida",{"state":164,"count":161,"slug":165},"Illinois","illinois",{"state":167,"count":161,"slug":168},"Massachusetts","massachusetts",{"state":170,"count":161,"slug":171},"Ohio","ohio",{"state":173,"count":161,"slug":174},"Tennessee","tennessee",{"state":176,"count":161,"slug":177},"Virginia","virginia",{"state":179,"count":180,"slug":181},"Maryland",4,"maryland",{"state":183,"count":180,"slug":184},"Michigan","michigan",{"state":186,"count":180,"slug":187},"Minnesota","minnesota",{"state":189,"count":180,"slug":190},"North Carolina","north-carolina",{"state":192,"count":193,"slug":194},"Arizona",3,"arizona",{"state":196,"count":193,"slug":197},"Colorado","colorado",{"state":199,"count":193,"slug":200},"Georgia","georgia",{"state":202,"count":193,"slug":203},"Oklahoma","oklahoma"]